Compound News and Research

RSS

Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers

A single type of cell in the lining of the bladder is responsible for most cases of invasive bladder cancer, according to researchers at the Stanford University School of Medicine.

21 Apr 2014

Researchers devise new approach to treatment of Alzheimer's disease

A team of researchers from Columbia University Medical Center, Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer's disease involving the so-called retromer protein complex. Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating the potentially toxic byproduct amyloid-beta, which is thought to contribute to the development of Alzheimer's.

21 Apr 2014

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941.

18 Apr 2014

Scientists develop microbicide gel that prevents transmission of multiple STIs in vagina/rectum in animals

Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections (STIs) in both the vagina and rectum in animals: HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV).

18 Apr 2014

Global cancer profiling market expected to grow $54.8 billion by 2018

Global Information Inc. announces the addition of a new market research report "Cancer Profiling and Pathways: Technologies and Global Markets" at GIIResearch.com.

18 Apr 2014

Nora Therapeutics closes $18M Series B financing to expand drug development

Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced the closing of an $18 million Series B financing.

17 Apr 2014

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* 'orphan drug designation' for the treatment of patients with acute myeloid leukaemia (AML).

17 Apr 2014

Study shows R9-caPep compound blocks PCNA actions in neuroblastoma cells

Neuroblastoma is one of the deadliest childhood cancers, accounting for 15 percent of pediatric cancer deaths. For patients with high-risk neuroblastomas, the five-year survival rate is 40 to 50 percent even with the most rigorous treatments available today.

17 Apr 2014

Neurovive presents new breakthrough on energy regulation at cellular level

NeuroVive, a leading mitochondrial medicine company, is presenting a breakthrough in the company's work on energy regulation at the cellular level.

17 Apr 2014

Researchers develop new technique for discovering natural compounds that form basis of novel therapeutic drugs

Researchers at Griffith University's Eskitis Institute have developed a new technique for discovering natural compounds which could form the basis of novel therapeutic drugs.

17 Apr 2014

Wilson Therapeutics closes $40 million Series B financing

Wilson Therapeutics, a biopharmaceutical company, today announced that it has closed a $40 million Series B financing co-led by new investors, Abingworth LLP and MVM Life Science Partners LLP. The company's founding investor, HealthCap, also participated in the round.

16 Apr 2014

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle.

15 Apr 2014

Findings pave way for potential therapy to combat H1N1 flu virus

Flu epidemics cause up to half a million deaths worldwide each year, and emerging strains continually threaten to spread to humans and cause even deadlier pandemics. A study by McGill University professor Maziar Divangahi published by Cell Press on April 10 in the journal Immunity reveals that a drug that inhibits a molecule called prostaglandin E2 (PGE2) increases survival rates in mice infected with a lethal dose of the H1N1 flu virus.

11 Apr 2014

Scientists identify enzyme that could be a useful target in treating asthma, cancer

In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies.

11 Apr 2014

Natural compound from green tomatoes protects against muscle atrophy

Using a screening method that previously identified a compound in apple peel as a muscle-boosting agent, a team of University of Iowa scientists has now discovered that tomatidine, a compound from green tomatoes, is even more potent for building muscle and protecting against muscle atrophy.

10 Apr 2014

New lab at the Nencki Institute conducts research on neurodegenerative diseases

The Laboratory of Preclinical Studies of Higher Standard, the newest lab of the Neurobiology Center at the Nencki Institute in Warsaw, Poland, will conduct basic research aimed to explain molecular mechanisms responsible for neurodegenerative diseases.

9 Apr 2014

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first findings from Company research aimed at optimizing the dosing of its IMGN853 product candidate.

9 Apr 2014

Researchers identify novel compound effective against drug-resistant lung cancer

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.

9 Apr 2014

Researchers identify experimental drugs to block treatment-resistant leukemia

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.

9 Apr 2014

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have submitted new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for the investigational products daclatasvir (DCV), an NS5A replication complex inhibitor, and asunaprevir (ASV), a NS3 protease inhibitor.

8 Apr 2014

Compound News and Research

Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers

Researchers devise new approach to treatment of Alzheimer's disease

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Scientists develop microbicide gel that prevents transmission of multiple STIs in vagina/rectum in animals

Global cancer profiling market expected to grow $54.8 billion by 2018

Nora Therapeutics closes $18M Series B financing to expand drug development

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Study shows R9-caPep compound blocks PCNA actions in neuroblastoma cells

Neurovive presents new breakthrough on energy regulation at cellular level

Researchers develop new technique for discovering natural compounds that form basis of novel therapeutic drugs

Wilson Therapeutics closes $40 million Series B financing

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Findings pave way for potential therapy to combat H1N1 flu virus

Scientists identify enzyme that could be a useful target in treating asthma, cancer

Natural compound from green tomatoes protects against muscle atrophy

New lab at the Nencki Institute conducts research on neurodegenerative diseases

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

Researchers identify novel compound effective against drug-resistant lung cancer

Researchers identify experimental drugs to block treatment-resistant leukemia

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News